check_circleStudy Completed

Postmenopause, Hormone Replacement Therapy

Bayer Identifier:

91052

ClinicalTrials.gov Identifier:

Not Available

EudraCT Number:

Not Available

EU CT Number:

Not Available
Study to assess safety of a hormone therapy preparation containing Drospirenone/Estradiol in women with concomitant disease and medication known to potentate the risk of hyperkalemia

Trial purpose

Please see attached Study Results Summary below.

Key Participants Requirements

Sex

N/A

Age

N/A

Trial summary

Enrollment Goal
230
Trial Dates
December 2001 - March 2003
Phase
Phase 3
Could I Receive a placebo
N/A
Products
Angeliq (E2/DRSP, BAY86-4891)
Accepts Healthy Volunteer
N/A

Primary Outcome

Secondary Outcome

Trial design

A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety of the Hormone Replacement Therapy Combination Drug Product Drospirenone/Estradiol in Postmenopausal Women With Concomitant Disease and Medication Known to Potentiate the Risk of Hyperkalemia
Trial Type
Interventional
Intervention Type
N/A
Trial Purpose
N/A
Allocation
N/A
Blinding
N/A
Assignment
N/A
Trial Arms
N/A

Additional Information

Click here and search for drug information provided by the FDA.Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.Click here to find results for studies related to marketed products.